Loading clinical trials...
Loading clinical trials...
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Conditions
Interventions
Aceclidine+Brimonidine combination ophthalmic solution
Aceclidine ophthalmic solution
+1 more
Locations
25
United States
Site #106
Chandler, Arizona, United States
Site #121
Mesa, Arizona, United States
Site #122
Phoenix, Arizona, United States
Site #124
Phoenix, Arizona, United States
Site #128
Scottsdale, Arizona, United States
Site #125
Sun City, Arizona, United States
Start Date
December 19, 2022
Primary Completion Date
December 15, 2023
Completion Date
January 25, 2024
Last Updated
February 25, 2026
NCT07322302
NCT07444658
NCT05458323
NCT05414994
NCT06060041
NCT06996353
Lead Sponsor
LENZ Therapeutics, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions